Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.
作者信息
Sudlow Cathie L M, Counsell Carl E
机构信息
Department of Clinical Neurosciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2XU.
出版信息
BMJ. 2003 Feb 15;326(7385):388-92. doi: 10.1136/bmj.326.7385.388.
Abstract
摘要
相似文献
1
Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis.
BMJ. 2003 Feb 15;326(7385):388-92. doi: 10.1136/bmj.326.7385.388.
2
Continuing the multiple sclerosis risk sharing scheme is unjustified.
BMJ. 2010 Jun 3;340:c1786. doi: 10.1136/bmj.c1786.
3
Commentary: Scheme has benefited patients.
BMJ. 2010 Jun 3;340:c2707. doi: 10.1136/bmj.c2707.
4
The multiple sclerosis risk sharing scheme.
BMJ. 2010 Jun 3;340:c2882. doi: 10.1136/bmj.c2882.
5
The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.
BMC Neurol. 2009 Jan 6;9:1. doi: 10.1186/1471-2377-9-1.
6
Multiple sclerosis risk sharing scheme: a costly failure.
BMJ. 2010 Jun 3;340:c1672. doi: 10.1136/bmj.c1672.
7
UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model.
BMJ Open. 2014 Jan 17;4(1):e004073. doi: 10.1136/bmjopen-2013-004073.
8
Shared scheme for assessing drugs for multiple sclerosis: cost effective provision of effective treatments for multiple sclerosis.
BMJ. 2003 May 31;326(7400):1212. doi: 10.1136/bmj.326.7400.1212.
9
Bad decision NICE.
Lancet. 2002 Feb 2;359(9304):447. doi: 10.1016/s0140-6736(02)07582-7.
10
Shared scheme for assessing drugs for multiple sclerosis: dealing with uncertainties about cost effectiveness of treatments is difficult problem.
BMJ. 2003 May 31;326(7400):1212-3. doi: 10.1136/bmj.326.7400.1212-a.
引用本文的文献
1
Barriers and Opportunities for Implementation of Outcome-Based Spread Payments for High-Cost, One-Shot Curative Therapies.
Front Pharmacol. 2020 Dec 8;11:594446. doi: 10.3389/fphar.2020.594446. eCollection 2020.
2
Dynamic Learning of Patient Response Types: An Application to Treating Chronic Diseases.
Manage Sci. 2018 Aug;64(8):3469-3970. doi: 10.1287/mnsc.2017.2793. Epub 2017 Aug 21.
3
Risk-Sharing Agreements in the EU: A Systematic Review of Major Trends.
Pharmacoecon Open. 2018 Jun;2(2):109-123. doi: 10.1007/s41669-017-0044-1.
4
Valorising and creating access to innovative medicines in the European union.
Front Pharmacol. 2011 Oct 11;2:57. doi: 10.3389/fphar.2011.00057. eCollection 2011.
5
Using comparative effectiveness research to inform policy and practice in the UK HHS: past, present and future.
Pharmacoeconomics. 2010;28(10):799-811. doi: 10.2165/11535260-000000000-00000.
6
Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers.
BMC Health Serv Res. 2010 Jun 7;10:153. doi: 10.1186/1472-6963-10-153.
7
Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.
Pharmacoeconomics. 2010;28(2):109-11. doi: 10.2165/11530860-000000000-00000.
8
Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.
BMJ. 2009 Dec 2;339:b4677. doi: 10.1136/bmj.b4677.
9
The Multiple Sclerosis Risk Sharing Scheme Monitoring Study--early results and lessons for the future.
BMC Neurol. 2009 Jan 6;9:1. doi: 10.1186/1471-2377-9-1.
10
Having your cake and eating it: office of fair trading proposal for funding new drugs to benefit patients and innovative companies.
Pharmacoeconomics. 2008;26(2):91-8. doi: 10.2165/00019053-200826020-00001.
本文引用的文献
1
Interferon in relapsing-remitting multiple sclerosis.
Cochrane Database Syst Rev. 2001;2001(4):CD002002. doi: 10.1002/14651858.CD002002.
2
Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
Neurology. 2001 Jun 12;56(11):1496-504. doi: 10.1212/wnl.56.11.1496.
3
Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study.
Lancet. 2001 May 19;357(9268):1576-82. doi: 10.1016/s0140-6736(00)04725-5.
4
European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.
Ann Neurol. 2001 Mar;49(3):290-7.
5
Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group.
N Engl J Med. 2000 Sep 28;343(13):898-904. doi: 10.1056/NEJM200009283431301.
6
Disease-modifying drugs for multiple sclerosis: a rapid and systematic review.
Health Technol Assess. 2000;4(9):i-iv, 1-101.
7
The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsing-progressive multiple sclerosis: a re-evaluation.
Brain. 1999 Oct;122 ( Pt 10):1941-50. doi: 10.1093/brain/122.10.1941.
8
Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. The Once Weekly Interferon for MS Study Group.
Neurology. 1999 Sep 11;53(4):679-86. doi: 10.1212/wnl.53.4.679.
9
Interferons in the treatment of multiple sclerosis: do they prevent the progression of the disease?
Arch Neurol. 1998 Dec;55(12):1578-80. doi: 10.1001/archneur.55.12.1578.
Zotero 插件